|
A Comparison Study of Two Sustained Release Theophylline Preparations (Theo-24 and Theo-Dur) With Regard to Gastrointestinal Side Effects and Sleep Disturbances
Sponsor: G.D. Searle, Chicago, IL.
|
Efficacy, Utility MEDIX Ultrasonic Nebulizer
Sponsor: Fisons Corporation, Bedford, MA.
|
Efficacy of Tilade in the Management of Adult Patients with Reversible Obstructive Airways Disease Who Require Chronic Medication
Sponsor: Fisons Corporation, Bedford, MA.
|
An Evaluation of the Use of Ventolin Rotacaps and the Rotahaler in Asthmatic Patients
Sponsor: Glaxo, Research Triangle Park, NC.
|
Pilot Study to Determine the Efficacy of Proventil Repetabs, Compared to Oral Beta-Agonist in Preventing Nighttime Breakthrough of Asthma Symptoms
Sponsor: Systemetrics/McGraw Hill, Santa Barbara, CA.
|
Efficacy of Nebulized Tilade in the Management of Adult Patients with Reversible Obstructive Airways Disease Who Require Chronic Medication
Sponsor: Fisons Corporation, Bedford, MA.
|
Comparison of Efficacy and Safety of LY163892 to Augmentin in the Treatment of Lobar Pneumonia and Bronchopneumonia
Sponsor: Lilly Research Laboratories, Indianapolis, IN.
|
Nasalcrom User Survey
Sponsor: Johnston, Zabor and Associates, Research Triangle Park, NC.
|
An Evaluation To Determine the Efficacy of A New Household Dust Miticide
Sponsor: Fisons Corporation, Bedford, MA.
|
An Evaluation To Determine the Safety and Efficacy of Cetirizine in Patients With Allergic Rhinitis
Sponsor: Pfizer Pharmaceuticals, New York, NY.
|
An Evaluation to Determine The Efficacy Tolerance and Safety of Temafloxacin vs. Augmentin In Patients With Bronchitis
Sponsor: Abbott Laboratories, Abbott Park, IL.
|
An Evaluation to Determine the Efficacy and Safety of Fluticasone Propionate Aqueous Nasal Spray Versus Astemizole Versus Placebo in Patients With Allergic Rhinitis
Sponsor: Glaxo, Research Triangle Park, NC.
|
An Evaluation to Compare Oral Cefpodoxime Proxetil (DOXEF Tablets) with Oral Amoxicillin/Clavulanate (Augmentin) in the Treatment of Acute Maxillary Sinusitis in Adults
Sponsor: Upjohn, Kalamazoo, Michigan
|
An Evaluation to Compare the Efficacy and Safety of Nedocromil Sodium 0,5% Nebulizer Solution Versus Placebo in Children 2-4 Years of Age with Bronchial Asthma
Sponsor: Fisons Corporation, Rochester, New York
|
A Multicenter Double-Blind, Parallel Group, Randomized Comparison of Ebastine versus Placebo in Children 6 Through 11 Years of Age with Seasonal Ragweed Allergy
Sponsor: Rhone-Poulenc Rorer, Collegeville, PA.
|
An Evaluation to Compare the Efficacy and Safety of Nedocromil Sodium 0.5% Nebulizer Solution Versus Placebo in Children 5 to 11 Years of Age with Bronchial Asthma
Sponsor: Fisons Corporation, Rochester, New York
|
An Evaluation to Compare the Efficacy and Safety of Ebastine 5 mg Versus Placebo in Adults With Perennial Allergic Rhinitis
Sponsor: Rhone-Poulenc Rorer, Collegeville, PA.
|
An Evaluation of Tilade in Symptomatic Patients with Mild to Moderate Asthma
Sponsor: Fisons Corporation, Rochester, New York.
|
An Evaluation to Compare the Efficacy and Safety of Cefdinir (600 rag qd and 300 mg bid) versus Augmentin (500 mg tid) in the Treatment of Adults With Acute Maxillary Sinusitis
Sponsor: Parke Davis Corporation, Ann Harbor, Ml.
|
An Evaluation to Compare the Efficacy and Safety of Zileuton 400 mg QID and 600 mg QID vs Beclomethasone in moderate asthma
Sponsor: Abbott Laboratories, Abbott Park, IL.
|
An Evaluation to Compare the Safety and Efficacy of Nasacort (220 meg/day) vs. Claritin (10 mg/day) in Patients With Seasonal Ragweed Induced Allergic Rhinitis
Sponsor: Rhone-Poulenc Rorer, Collegeville, PA.
|
An Evaluation to Compare the Safety and Efficacy of Rhinocort Vs. Beconase in Patients with Seasonal Allergic Rhinitis
Sponsor: Astra, USA, Radnor, PA.
|
An Evaluation to Compare the Safety and Efficacy of Ciprofloxacin versus Clarithromycin in the Treatment of Patients with Acute Sinusitis
Sponsor: Miles Incorporated, West Haven, CT.
|
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Safety and Efficacy of Cromolyn Sodium Inhalation Solution in an Isotonic Formulation in Pediatrics
Sponsor: Dey Laboratories, Napa, CA.
|
A Study For Long-Term Surveillance of Zileuton Plus Ususal Carevs Usual Care in Patients with Asthma
Sponsor: Abbott Laboratories, Abbott Park,IL.
|
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Efficacy and Safety of Chlorofluorocarbon (CFC) andNon-CFC Formulations of Intal (Cromolyn Sodium) Metered Dose Inhaler (MDI) 2 mg QID in the Treatment of Asthma in Patients 12 years and Older Using PRN B2 Agonists Administered by MDI
Sponsor: Fisons Corporation, Rochester, NY.
|
A Randomized, Double-Blind, Parallel Group Evaluation of Salmeterol vs. Placebo in the Treatment of Nocturnal Asthma
Sponsor: Glaxo, Inc., Research Triangle Park, NC.
|
Pilot Study for ENACT Health Management Systems. Inc., A Computerized Hand-Held Peak Flow Meter (AIRWATCH) Versus ASSESS Peak Flow Meter in Asthmatic Patients
Sponsor: ENACT Health Management Systems, Inc.
|
A Randomized, Double-Blind, Placebo Controlled Evaluation of the Efficacy and Safety of Azmacort Forte HFA-134A Oral Inhaler Compared to Azmacort Oral Inhaler in the Treatment of Asthma
Sponsor: Rhone-Poulenc Rorer Pharmaceuticals, Inc. Collegeville, PA.
|
An Open-Labeled Study of the Efficacy and Safety of Non-Chlorofluoro-carbon Formulation of Intal (Cromolyn Sodium) Metered Dose Inhaler in the Treatment of Asthma in Patients 12 Years and Older
Sponsor: Fisons, Inc., Rochester, NY.
|
A Randomized, Double-Blind, Double-Dummy, Parallel Group, Comparative Clinical Trial of the Effects of 50MCG and 25MCG Salmeterol Powder b.i.d. Via the Diskus Vs. Ventolin Rotacaps 200 MCG q.i.d. Vs. Placebo in Pediatric Subjects Aged 4-11 Years with Mild to Moderate Asthma
Sponsor: Glaxo, Inc. Research Triangle Park, NC.
|
A Randomized, Double-Blind Study of the Safety and Efficacy of ABT-761 150 mg, 300 mg qd Versus Placebo in Moderate Asthma
Sponsor: Abbott Laboratories, Chicago, Illinois.
|
An Open Label, Non-comparative, Multicenter Trial to Evaluate Accolate in Patients with Asthma
Sponsor: Zeneca Pharmaceuticals.
|
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Two Doses of SB 205312 Administered as an Oral Suspension (75 mg b.i.d. and 150 mg b.i.d.) for 12 Weeks in Pediatric Outpatients With Asthma
Sponsor: SmithKline Beecham, Collegeville, PA.
|
A Long-Term Safety Study of Zileuton Controlled-Release Plus Usual Care Vs. Placebo Plus Usual Care in Patients with Asthma
Sponsor: Abbott Laboratories, Abbott Park, IL.
|
A Study of the Genetic Component of ALT Elevations in Patients Previously Treated with Zileuton (Zyflo)
Sponsor: Abbott Laboratories, Abbott Park, IL.
|
An Evaluation of the Effects of Claritin Vs. Benadryl on General Behavior and School Attendance and Performance in Children 6-11 Years of Age With Seasonal Allergic Rhinitis
Sponsor: Schering Laboratories, Kenilworth, NJ.
|
Multicenter Double-Blind Placebo Controlled, Randomized, Comparative Study to Compare the Efficacy and Safety of Ebastine 20 mg., Ebastine 10 mg., Loratadine 10 mg and Placebo All Given Once Daily for Four Weeks in the Treatment of Seasonal Allergic Rhinitis
Sponsor: Rhone-Poulenc Rorer, Collegeville, PA.
|
An Open Label Multicenter Study of the Efficacy, Safety and Effect on Quality of Life of Zyrtec (Cetirizine HCL) Syrup in the Treatment of Seasonal Allergic Rhinitis in Children
Sponsor: Pfizer Inc., New York, NY.
|
A Randomized, Double-Blind Study of Asteltn Nasal Spray Monotherapy vs. Combined Therapy With Both a Nasal Steroid and an Oral Antihistamine in Subjects with Seasonal Allergic Rhinitis
Sponsor: Wallace Laboratories, Cranberry, NJ.
|
A Prospective Randomized, Double-Blind Comparison of the Safety and Efficacy of Moxifloxacin 400 mg qd for Ten Days Vs. Cefuroxime Axetil 250 mg b.i.d. for Ten Days for the Treatment of Patients with Acute Bacterial Maxillary Sinusitis
Sponsor: Bayer Corp., West Haven, CT.
|
A Double-Blind, Placebo Controlled Study to Evaluate the Effects of Treatment of Seasonal Allergic Rhinitis in Patients with Co-Morbid Asthma and a History of Seasonal Exacerbations of Asthma or Medical Resources Utilization
Sponsor: Schering-Plough, Kenilworth, NJ.
|
A Randomized, Double-Blind, Placebo-Controlled Comparative Trial of Fluticasone Propionate 440 meg b.i.d. or 880 meg b.i.d. Vs. Placebo Administered Via Metered-Dose Inhaler in Propellant 11/12 or GR 106642X in Adolescent and Adult Corticosteroid-Dependent Asthmatics
Sponsor: GlaxoWellcome, Inc., Research Triangle Park, NC.
|
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety & Efficacy of Salmeterol/Fluticasone Propionate in Combination in GR106642X MDI, 50/25 meg b.i.d., and Satmeterol in Propellant PI 1/12 MDI, 50 meg b.i.d,, Fluticasone Propionate in Propellant PI 1/12 MDI 250 meg b.i.d., and Placebo in Propellant GR106642X MDI in Adolescent and Adult Subjects with Asthma
Sponsor: GlaxoWellcome, Inc., Research Triangle Park, NC.
|
An Applied Health Outcomes Measurement Program That Provides A Cross-Sectional Profile of Both New and Established Patients
Sponsor: Schering Laboratories, Kenilworth, NJ.
|
A Randomized, Double-Blind, Double-Dummy, Multicentre Study to Compare the Relative Clinical Potency and Safety of a Flexible Aerosol and Fluticasone Propionate Inhalation Aerosol for Eight to Sixteen Weeks in Inhaled Steroid Dependent Adult Asthmatics
Sponsor: Rhone-Poulenc Rorer, Collegeville, PA.
|
A Multi-Center Study to Investigate Genetic Polymorphisms in Subjects with Severe Asthma Dependent on Daily Doses of Oral Corticosteroids
Sponsor: GlaxoWellcome, Inc., Research Triangle Park, NC
|
A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12 Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100 meg BID via the Diskus Inhaler vs. Oral Montelukast 10 mg QD in Adolescents and Adults with Persistent Asthma
Sponsor: GlaxoWellcome, Inc., Research Triangle Park, NC.
|
A Five-week, Randomized, Double-Blind, Double-Dummy Two Period, Four Treatment Crossover, Placebo-Controlled, Balanced Incomplete Block Design, Multi-Center Study of Salmeterol Xinafoate Inhalation Aerosol, 25 Meg Bid, 25 Meg Tid, 50 Meg. Bid and Placebo Administered via a Holding Chamber with Facemask in Subjects with Asthma Aged 24-47 Months
Sponsor: GlaxoWellcome, Inc; Research Triangle Park, NC
|
Study for the Efficacy and Safety of Combination Loratadine/Montelukast QD Versus Its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis in Patients 15 Years of Age and Older
Sponsor: Schering-Plough Research Institute; Kenilworth, NJ
|
A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Fluticasone Propionate Inhalation Powder (50/ig) via Diskus with Oral Montelukast (5mg QD) Chewable Tablets in Children 6-12 Years of Age with Persistent Asthma
Sponsor: GlaxoWellcome, Inc; Research Triangle Park, NC
|
An Efficacy, Safety, and Tolerability Study of Daily Dosing with Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects 2-5 Years Old with Asthma
Sponsor: Sepracor Inc; Marlborough, MA
|
A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100^g Diskus Inhaler b.i.d. versus Fluticasone Propionate 250,ug Diskus Inhaler b.i.d. in Adolescents and Adults with Moderate Persistent Asthma
Sponsor: GlaxoWellcome, Inc.
|
A Multicenter Double-Blind Placebo Controlled Randomized Clinical Trial to Compare the Efficacy and Safety of Ebastine 20mg, Loratadine lOmg, and placebo, All Given Once Daily for Four Weeks in the Treatment of Seasonal Allergic Rhinitis
Sponsor: Aimirall Prodesfarma, S.A., Barcelona, Spain
|
A Stratified, Randomized, Double-blind, Placebo Controlled, Parallel Group, 32 Week Trial Evaluating the Safety and Efficacy of the Fluticasone Propionate/Salmeterol Diskus Combination Product 100/50^g Once Daily Versus Fluticasone Propionate Diskus lOO^g Once Daily and Placebo in Symptomatic Pediatric Subjects (4 to 11 Years) with Asthma
Sponsor: GlaxoSmithKline; Research Triangle Park, NC
|
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast with Perennial Allergic Rhinitis
Sponsor: Merck & Co., Inc.; Whitehouse Station, New Jersey
|
A Phase III Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Placebo-Controlled, Efficacy & Safety Study of Ciclesonide MDI 400>g/day, 800>g/day (Ex-Valve) and Flovent MDI (Fluticasone Propionate) 880jUg/day (Ex-Acuator) Administered Twice Daily for 12 weeks in the Treatment of Severe Persistent Asthma in Adolescents and Adults
Sponsor: Aventis Pharmaceuticals
|
A Double-Blind, Placebo and Active-Controlled, Parallel Group Study of Tecastemizole Administered to Subjects with Seasonal Allergic Rhinitis
Sponsor: Sepracor, Inc.; Marlborough, MA.
|
A Twelve-Week, Randomized, Double-Blind, Double-Dummy Trial of Symbicort (40/4.5/^g) vs its mono-products (budesonide and formoterol) in Asthmatic Children Aged Six-Fifteen Years
Sponsor: AstraZeneca LP; Wilmington, DE.
|
A three-year observational study of the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR)
Sponsor: Genentech, Inc.
|
A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180mg in the Treatment of Subjects with Symptomatic Seasonal Allergic Rhinitis (SAR)
Sponsor: Integrated Therapeutics Group, Inc., Kenihvorth, NJ.
|
Currently conducting a Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS BID or Fluticasone Propionate lOOmcg DISKUS BID Alone
Sponsor: GlaxoSmithKline, Research Triangle Park, North Carolina.
|
A Randomized, Double-Blind Trial of Astelin (azelastine hydrochloride) Nasal Spray Compared to Zyrtec (cetrizine hydrochloride) in Patients with Seasonal Allergies
Sponsor: MedPointe Pharmaceuticals.
|
Safety and Efficacy of Olopatadine Hydrochloride Nasal Spray in Pediatric Patients
Sponsor: Alcon Research
|
